# What common knee treatments can and cannot do *non-surgical knee treatment mesa — What the Choices Can Do* > non-surgical knee treatment mesa choices explained plainly, including likely relief and clear limits. ## Treatment can ease soreness without rebuilding the knee Here you'll see what common knee choices can change and what they can't. Some calm swelling, while others reduce pressure or strengthen the leg. Less soreness doesn't mean the worn joint surface has grown back. Keep that difference in mind when you compare knee replacement alternatives. ## Exercise helps the muscles support the joint Thigh and hip muscles guide the knee and absorb part of each step. When those muscles tire, the sore joint carries more of the load. Slow strength work can improve control during standing and walking. It won't erase wear, but daily movement may become easier. Begin with motion that doesn't sharply raise the soreness. Try a brief walk or several easy chair rises. Add a little time or effort, then check the knee later. If swelling or aching keeps climbing, ask a clinician to adjust the exercise. ## Braces and medicine have narrower jobs A brace can move pressure when one side of the knee bears more weight. A cane shares some weight during each step. Neither repairs the worn surface, so judge them by comfort and walking. A support that stays in the closet can't help. Anti-inflammatory medicine can quiet the body's swelling response around an irritated joint. That may ease soreness, but pills can affect the stomach, kidneys or heart. Your doctor or pharmacist can check those risks against your current medicines. Don't add or stop a drug because of a website. ## A treatment visit should begin with an exam The same ache can start in different parts of the knee. During an exam, the clinician checks movement, puffiness, leg power and tenderness. Questions about old injuries and quick changes add needed detail. Together, those findings help match the treatment to the knee being examined. Have the clinician name the expected result and how long it may take. Ask about cost, recovery time and risks tied to your health. At home, note sleep, walking and swelling so you can describe any change. After examining you, QC Kinetix medical providers can prepare PRP by spinning your blood for extra clot-forming platelets, place it in the knee and offer it as one regenerative treatment option. ## Sources 1. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI. Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. 2. A systematic review and meta-analysis of 169 randomised trials (21,163 participants) of viscosupplementation for knee OA found clear evidence of small-study effects and publication bias. The prespecified main analysis, restricted to 24 large placebo-controlled trials with at least 100 participants per group (8,997 randomised), found a pain reduction of SMD -0.08 (95% CI -0.15 to -0.02) - the confidence interval excluding the prespecified minimal clinically important difference of -0.37. Pereira TV, Jüni P, Saadat P, et al. — [Viscosupplementation for knee osteoarthritis: systematic review and meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/36333100/). *BMJ*, 2022. DOI: 10.1136/bmj-2022-069722. 3. A meta-analysis of 16 randomised trials (807 participants) of intra-articular mesenchymal stem cells for chronic knee pain from osteoarthritis found that at 3-6 months MSC therapy probably produces little to no difference in pain (WMD -0.74cm on a 10cm VAS, 95% CI -1.16 to -0.33, against a minimally important difference of 1.5cm) or physical function, both moderate certainty; at 12 months, probably little to no difference in pain. MSC therapy may increase the risk of any adverse event (RR 2.67, 95% CI 1.19 to 5.99) and of knee pain and swelling (RR 1.58, 95% CI 1.04 to 2.38). Sadeghirad B, Rehman Y, Khosravirad A, et al. — [Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.](https://pubmed.ncbi.nlm.nih.gov/38777213/). *Osteoarthritis and Cartilage*, 2024. DOI: 10.1016/j.joca.2024.04.021. 4. In a randomised sham-controlled trial of genicular artery embolization for mild-to-moderate knee osteoarthritis unresponsive to conservative treatment (58 patients, 29 per arm), pain scores improved substantially in BOTH arms over 12 months (44.44 to 65.61 with GAE; 42.34 to 58.15 with sham), with no significant between-group difference (7.46, 95% CI -13.63 to 28.56, p=0.25) and no significant change in synovitis. The authors concluded the results suggest a sustained placebo effect and do not support clinical implementation of GAE. van Zadelhoff TA, van der Heijden RA, Bierma-Zeinstra SMA, et al. — [Long-term outcomes of genicular artery embolization for knee osteoarthritis: 12-month efficacy and secondary outcomes from a randomized sham-controlled clinical trial.](https://pubmed.ncbi.nlm.nih.gov/42009866/). *European Radiology*, 2026. DOI: 10.1007/s00330-026-12505-8. 5. A network meta-analysis of 149 randomised knee-osteoarthritis trials evaluating different placebo types found that intra-articular placebo produced a significant pain effect of its own (effect size 0.29, 95% credible interval 0.09 to 0.49) relative to oral placebo - meaning any uncontrolled injection appears to work partly because it is an injection, and open-label injection results systematically overstate benefit. Bannuru RR, McAlindon TE, Sullivan MC, et al. — [Effectiveness and Implications of Alternative Placebo Treatments: A Systematic Review and Network Meta-analysis of Osteoarthritis Trials.](https://pubmed.ncbi.nlm.nih.gov/26215539/). *Annals of Internal Medicine*, 2015. DOI: 10.7326/M15-0623. 6. A meta-analysis of nine randomised trials of arthroscopic surgery for degenerative knee disease in middle-aged and older patients found a small pain benefit (effect size 0.14, 95% CI 0.03 to 0.26), equal to 2.4mm on a 0-100mm visual analogue scale, present at 3 and 6 months but gone by 24 months, and no significant benefit for physical function (effect size 0.09, 95% CI -0.05 to 0.24). Documented harms included symptomatic deep venous thrombosis (4.13 events per 1,000 procedures, 95% CI 1.78 to 9.60), pulmonary embolism, infection and death. Thorlund JB, Juhl CB, Roos EM, et al. — [Arthroscopic surgery for degenerative knee: systematic review and meta-analysis of benefits and harms.](https://pubmed.ncbi.nlm.nih.gov/26080045/). *BMJ*, 2015. DOI: 10.1136/bmj.h2747. 7. In the FIDELITY trial, 146 patients aged 35-65 with a degenerative medial meniscus tear and no knee osteoarthritis were randomised double-blind to arthroscopic partial meniscectomy or sham surgery. There was no significant between-group difference at 12 months in Lysholm score (-1.6 points, 95% CI -7.2 to 4.0), WOMET score (-2.5, 95% CI -9.2 to 4.1) or knee pain after exercise (-0.1, 95% CI -0.9 to 0.7). Sihvonen R, Paavola M, Malmivaara A, et al. — [Arthroscopic partial meniscectomy versus sham surgery for a degenerative meniscal tear.](https://pubmed.ncbi.nlm.nih.gov/24369076/). *New England Journal of Medicine*, 2013. DOI: 10.1056/NEJMoa1305189. 8. FDA states directly that regenerative medicine therapies - including stem cells, stromal vascular fraction, umbilical cord blood, amniotic fluid, Wharton's jelly, ortho-biologics and exosomes - have NOT been approved for the treatment of any orthopedic condition, naming osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain. FDA further states that being charged for these products, or being offered them outside an FDA-overseen clinical trial, means a patient is likely being deceived and offered a product illegally, and that a product's presence on clinicaltrials.gov or a firm's FDA registration does not mean the product is legally marketed. Reported harms include blindness, tumor formation, neurological events and life-threatening bacterial infections. US Food and Drug Administration, Center for Biologics Evaluation and Research — [Important Patient and Consumer Information About Regenerative Medicine Therapies](https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies). *FDA.gov*, 2021. 9. A Bayesian network meta-analysis restricted to LARGE randomized trials (>=100 patients per group) of 18 intra-articular interventions in knee and hip OA found treatment effects were larger in the 35 high-risk-of-bias trials than in the 22 low/unclear-risk trials. Excluding high-risk trials, triamcinolone had the highest probability of exceeding the minimal important difference at weeks 2 and 6; hyaluronic acid had NO effect on pain (SMD -0.04, 95% CrI -0.19 to 0.11) but higher odds of dropouts due to adverse events (OR 2.01) and of serious adverse events (OR 1.86) than placebo. Effects of 16 of the 18 interventions were smaller than the MID and most were consistent with placebo. da Costa BR, et al. — [Effectiveness and safety of intra-articular interventions for knee and hip osteoarthritis based on large randomized trials: A systematic review and network meta-analysis.](https://pubmed.ncbi.nlm.nih.gov/39265924/). *Osteoarthritis and Cartilage*, 2025. DOI: 10.1016/j.joca.2024.08.014. 10. A Cochrane review of 27 trials (1,767 participants) of intra-articular corticosteroid versus sham or no treatment in knee OA graded the quality of evidence as LOW for all outcomes, citing inconsistent effect estimates, wide variation across trials and imprecise pooled results. Juni P, Hari R, Rutjes AW, et al. — [Intra-articular corticosteroid for knee osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/26490760/). *Cochrane Database of Systematic Reviews*, 2015. DOI: 10.1002/14651858.CD005328.pub3. 11. The RESTORE trial randomized 288 adults aged 50+ with symptomatic mild-to-moderate medial knee OA to three weekly leukocyte-poor PRP injections or saline placebo. At 12 months, pain change was -2.1 vs -1.8 points (difference -0.4; 95% CI -0.9 to 0.2; P=.17) and medial tibial cartilage volume change was -1.4% vs -1.2% (P=.81). 29 of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings 'do not support use of PRP for the management of knee OA.' Bennell KL, Paterson KL, Metcalf BR, et al. — [Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.](https://pubmed.ncbi.nlm.nih.gov/34812863/). *JAMA*, 2021. DOI: 10.1001/jama.2021.19415. ## A knee exam can clarify the next choice QC Kinetix provides regenerative treatment options, including PRP; medical providers spin a sample of your blood and place its prepared portion in the knee. They can examine the joint, hear what limits you and discuss whether that procedure fits. No result is promised, and there is no charge for the consultation. For most Mesa residents, the Chandler location is on South Dobson Road. Call (602) 837-PAIN or use the booking link to arrange the visit. Have your current medicines and a brief symptom history ready. Book a free consultation: --- Understand the soreness. Know your choices. Plain information about an aching knee, useful self-care, urgent symptoms and non-surgical choices near Mesa. Plain help for understanding knee soreness, home care and nearby choices. This site is operated by the owners of the QC Kinetix Phoenix-area clinics, including the Chandler, Scottsdale, Peoria and Banner Estrella locations, and those owners benefit when readers book a consultation. © 2026 Mesa Knee Evidence Room. General education only; an in-person clinician should assess your own knee and urgent warning signs.